Amgen (AMGN) EBITDA (2016 - 2026)

Amgen has reported EBITDA over the past 18 years, most recently at $2.7 billion for Q1 2026.

For Q1 2026, EBITDA rose 126.32% year-over-year to $2.7 billion; the TTM value through Mar 2026 reached $10.6 billion, up 41.95%, while the annual FY2025 figure was $9.1 billion, 25.1% up from the prior year.
EBITDA for Q1 2026 was $2.7 billion at Amgen, down from $2.7 billion in the prior quarter.
Over five years, EBITDA peaked at $2.7 billion in Q4 2025 and troughed at $991.0 million in Q1 2024.
A 5-year average of $2.1 billion and a median of $2.2 billion in 2022 define the central range for EBITDA.
Biggest five-year swings in EBITDA: skyrocketed 162.8% in 2022 and later crashed 48.41% in 2024.
Year by year, EBITDA stood at $2.2 billion in 2022, then tumbled by 43.0% to $1.3 billion in 2023, then surged by 81.83% to $2.3 billion in 2024, then increased by 17.7% to $2.7 billion in 2025, then fell by 1.99% to $2.7 billion in 2026.
Business Quant data shows EBITDA for AMGN at $2.7 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.5 billion in Q3 2025.

Peer Comparison